INT89217

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.50
First Reported 2000
Last Reported 2009
Negated 1
Speculated 0
Reported most in Abstract
Documents 8
Total Number 8
Disease Relevance 12.32
Pain Relevance 0.51

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (ADAMTS13) extracellular space (ADAMTS13) extracellular region (ADAMTS13)
proteinaceous extracellular matrix (ADAMTS13)
Anatomy Link Frequency
platelet 2
B12 2
plasma 1
ADAMTS13 (Homo sapiens)
Pain Link Frequency Relevance Heat
anesthesia 2 92.80 High High
cINOD 7 86.44 High High
spastic colon 1 84.16 Quite High
abdominal pain 1 69.76 Quite High
cytokine 5 25.16 Quite Low
Inflammation 6 24.76 Low Low
palliative 7 5.00 Very Low Very Low Very Low
cva 6 5.00 Very Low Very Low Very Low
antagonist 6 5.00 Very Low Very Low Very Low
corticosteroid 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hemolytic Uremic Syndrome 52 100.00 Very High Very High Very High
Thrombotic Thrombocytopenic Purpura 21 100.00 Very High Very High Very High
Recurrence 107 99.16 Very High Very High Very High
Bacterial Meningitis 2 96.84 Very High Very High Very High
Thrombotic Microangiopathies 12 96.48 Very High Very High Very High
Communicable Diseases 2 95.52 Very High Very High Very High
Adhesions 4 94.16 High High
Heart Rate Under Development 3 94.00 High High
Infection 14 91.72 High High
Renal Failure 4 91.64 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Variety of genetic forms include HUS due to deficiencies of factor H, membrane cofactor protein, Von Willebrand factor-cleaving protease (ADAMTS 13) and intracellular defect in vitamin B12 metabolism.
Negative_regulation (deficiencies) of Von Willebrand factor-cleaving protease in B12 associated with hemolytic uremic syndrome
1) Confidence 0.50 Published 2006 Journal Nephrology (Carlton) Section Abstract Doc Link 16756634 Disease Relevance 1.92 Pain Relevance 0.09
Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura.
Negative_regulation (inhibitor) of ADAMTS 13 associated with thrombotic thrombocytopenic purpura
2) Confidence 0.42 Published 2004 Journal Am. J. Hematol. Section Title Doc Link 14755376 Disease Relevance 0.99 Pain Relevance 0.07
Variety of genetic forms include HUS due to deficiencies of factor H, membrane cofactor protein, Von Willebrand factor-cleaving protease (ADAMTS 13) and intracellular defect in vitamin B12 metabolism.
Negative_regulation (deficiencies) of ADAMTS 13 in B12 associated with hemolytic uremic syndrome
3) Confidence 0.41 Published 2006 Journal Nephrology (Carlton) Section Abstract Doc Link 16756634 Disease Relevance 1.92 Pain Relevance 0.09
Thrombotic thrombocytopenic purpura is caused by deficiency of von Willebrand factor cleaving protease (ADAMTS-13), resulting in endothelial cell-attached ultra-large von Willebrand multimers that readily bind to platelet surface receptors and cause platelet adhesion and aggregation [19].
Negative_regulation (deficiency) of ADAMTS-13 in platelet associated with thrombotic thrombocytopenic purpura and adhesions
4) Confidence 0.26 Published 2006 Journal Crit Care Section Body Doc Link PMC1750988 Disease Relevance 2.00 Pain Relevance 0.09
Thrombotic thrombocytopenic purpura is caused by deficiency of von Willebrand factor cleaving protease (ADAMTS-13), resulting in endothelial cell-attached ultra-large von Willebrand multimers that readily bind to platelet surface receptors and cause platelet adhesion and aggregation [19].
Negative_regulation (deficiency) of von Willebrand factor cleaving protease in platelet associated with thrombotic thrombocytopenic purpura and adhesions
5) Confidence 0.26 Published 2006 Journal Crit Care Section Body Doc Link PMC1750988 Disease Relevance 2.00 Pain Relevance 0.09
Therapeutic plasma exchange is a promising treatment for adults who develop HUS/TTP, but its role has yet to be determined definitively, either in a randomized controlled trial or by an international register of cases.
Negative_regulation (develop) of TTP in plasma associated with hemolytic uremic syndrome and thrombotic thrombocytopenic purpura
6) Confidence 0.18 Published 2000 Journal Symp Ser Soc Appl Microbiol Section Abstract Doc Link 10880176 Disease Relevance 1.20 Pain Relevance 0.08
The fact that TTP did not decrease significantly from first line to beyond second line treatment is especially noteworthy.
Neg (not) Negative_regulation (decrease) of TTP
7) Confidence 0.10 Published 2006 Journal BMC Cancer Section Abstract Doc Link PMC1431554 Disease Relevance 0.42 Pain Relevance 0
Patients with ADAMTS-13 deficiency present either with neonatal onset HUS or with a recurrent thrombotic thrombocytopenic purpura-like course.
Negative_regulation (deficiency) of ADAMTS-13 associated with hemolytic uremic syndrome and thrombotic thrombocytopenic purpura
8) Confidence 0.05 Published 2009 Journal Pediatr Nephrol Section Body Doc Link PMC2753770 Disease Relevance 1.87 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox